Utility of Metabolic Markers and Mitochondrial DNA in Blood, as Predictors of Long-Term Evolution in Patients With Thyroid Carcinoma

    The advance in the identification of metabolic and genetic markers related to thyroid carcinoma (TC) raises the possibility of using the expression of these markers in patients with CT to develop a predictive model of clinical evolution.

    Clinical follow-up was performed, with cervical ultrasound, thyroglobulin (Tg) levels, anti-Tg antibodies, and physical examination, during 36 months, of 18 patients operated on for thyroid carcinoma, and it was related to the preoperative determination of PFKB3 and Prx3 in plasma. In addition, mtDNA was isolated, identifying two fragments with clinical relevance.

    A good clinical evolution was observed, without recurrence in imaging tests or at a molecular level (Tg levels) in any patients with TC. Metabolic level showed that the levels of PFKB3, Prx3 and the ratio PFKB3 / Prx3 were higher in all the patients with good evolution carcinoma when compared with patients with benign pathology (hyperplasia), although without statistical significance. At the level of the mtDNA analysis, 2 fragments were identified, with fragment 1 levels higher in patients with benign pathology and fragment 2 higher in patients with TC, this elevation being constant in the 18 patients without recurrence of the disease.

    The alteration at the level of the expression of proteins such as PFKB3 and Prx3, or the increase of some fragments of mtDNA may be predictors of a good evolution in TC, but more studies are necessary, with a larger population of patients and comparison with patients with bad evolution to reach definitive conclusions.


Leave a Reply